Abstract
Cardiovascular disease is one of the main leading causes of mortality. Approximately, 80% of cardiovascular deaths occur in low- and middle-income countries (LMICs). Current guidelines which are based on randomized controlled trials direct the cardiovascular diagnosis and treatment. Yet, such guidelines do not benefit every patient. Recent studies question the ‘one size fits all’ principle particularly in complex traits such as thrombosis. The cost and duration of genetic testing continue to decline rapidly and novel strategies are on the rise to determine individual susceptibility to diseases and responses to therapy. Multidimensional evaluation of the patient with his/her environment, genomics, detailed medical history, and compliance to treatment are crucial in preventing complications from antithrombotic treatment. In this review, we discuss some of the pharmacogenomic features of antithrombotic medications that are currently used. We believe current personalized medicine and pharmacogenomics are pivotal in elucidating contradictory results of randomized controlled trials to test the same antithrombotic regimen on all participants.
Keywords: Antiplatelet, antithrombotic theraphy, aspirin, cardiovascular therapeutics, clopidogrel, personalized medicine, pharmacogenomics.
Current Pharmacogenomics and Personalized Medicine
Title:Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries
Volume: 12 Issue: 3
Author(s): Pinar Kuru and Mehmet Agirbasli
Affiliation:
Keywords: Antiplatelet, antithrombotic theraphy, aspirin, cardiovascular therapeutics, clopidogrel, personalized medicine, pharmacogenomics.
Abstract: Cardiovascular disease is one of the main leading causes of mortality. Approximately, 80% of cardiovascular deaths occur in low- and middle-income countries (LMICs). Current guidelines which are based on randomized controlled trials direct the cardiovascular diagnosis and treatment. Yet, such guidelines do not benefit every patient. Recent studies question the ‘one size fits all’ principle particularly in complex traits such as thrombosis. The cost and duration of genetic testing continue to decline rapidly and novel strategies are on the rise to determine individual susceptibility to diseases and responses to therapy. Multidimensional evaluation of the patient with his/her environment, genomics, detailed medical history, and compliance to treatment are crucial in preventing complications from antithrombotic treatment. In this review, we discuss some of the pharmacogenomic features of antithrombotic medications that are currently used. We believe current personalized medicine and pharmacogenomics are pivotal in elucidating contradictory results of randomized controlled trials to test the same antithrombotic regimen on all participants.
Export Options
About this article
Cite this article as:
Kuru Pinar and Agirbasli Mehmet, Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries, Current Pharmacogenomics and Personalized Medicine 2014; 12 (3) . https://dx.doi.org/10.2174/1875692112666141027231225
DOI https://dx.doi.org/10.2174/1875692112666141027231225 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Current Diabetes Reviews Association of Hypothyroidism with Body Mass Index, Systolic Blood Pressure and Proteinuria in Diabetic Patients: Does treated Hypothyroidism with Thyroxine Replacement Therapy Prevent Nephropathy/Chronic Renal Disease?
Current Diabetes Reviews Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cell Implantation for Myocardial Disorders
Current Drug Delivery Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Silent Cerebral Damage in Hypertension
Current Hypertension Reviews Patents on Metallic Biodegradable Stents
Recent Patents on Materials Science Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA) – Animal Models as a Proof of Concept
Current Medicinal Chemistry Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Brain Oxidative Markers in Stress: Possible New Drug Targets Against Neuroinflammation
Current Neuropharmacology Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Cardiac Amyloid - A Hidden Contributor to Cardiac Dysfunction Following Cardiac Surgery: Case Report and Literature Review
Current Cardiology Reviews A Systematic Review of Digital and Computer-Based Alcohol Intervention Programs in Primary Care
Current Drug Abuse Reviews Type 2 Diabetes: An Atherothrombotic Syndrome
Current Molecular Medicine Effect of Hyperthermia and Triblock Copolymeric Nanoparticles as Quercetin Carrier on DU145 Prostate Cancer Cells
Current Nanoscience Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Non Alcoholic Fatty Liver: Epidemiology and Natural History
Reviews on Recent Clinical Trials Editorial (Thematic Issue: Natural Leads in Drug Discovery against Metabolic Disorders and their Related Infectious Diseases)
Current Topics in Medicinal Chemistry